Plain-English translation of NCT07596693 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing KXV01, a new type of personalized cancer treatment that uses your own immune system to fight your tumor. Doctors will collect a sample of your tumor, identify specific immune cells (called TCRs) that recognize your cancer, and grow millions of copies of these cells in the lab. You'll then receive an infusion of these custom-made cells designed specifically to attack your cancer.
Many patients with advanced solid tumors run out of treatment options because standard therapies stop working. This medication represents a new approach — instead of using the same treatment for everyone, it's customized to each person's individual cancer, which may help the immune system recognize and destroy tumor cells more effectively.
You likely qualify if…
You likely don't qualify if…
First, doctors will remove a small sample of your tumor to identify immune cells that recognize your cancer. Your blood will also be tested to ensure you're healthy enough for treatment. Then, if immune cells can be found and grown successfully in the lab, you'll return for an infusion of your personalized cells. You'll have follow-up visits to monitor how well the treatment works and watch for any side effects. This is a Phase 1 trial, meaning it's testing safety and tolerability in a small group of patients (about 30 people).
AI-generated summary from trial data · Sep 11, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
TCRx Therapeutics Co.Ltd
Collaborators
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Enrollment target
~30 participants
Started
December 2025
Primary completion
December 2027
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Weichi Zhou
TCRx Therapeutics Co.Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.